BETA

IPO registrations (S-1, F-1) · Registrants

Catalent, Inc.

SEC CIK
1596783 · filings on EDGAR ↗
Former names
PTS Holdings Corp. (2014–2014)
Registration
Form S-1, first filed 2014-01-24, last 2015-06-01; 3 initial registrations, 7 amendments
Outcome
Final prospectus filed 2014-08-01; declared effective 2014-07-30
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
14 SCHOOLHOUSE ROAD, Somerset, NJ 08873
EIN
20-8737688
EDGAR entity type
operating
Insiders and CEO pay
Catalent, Inc. on the corporate pages

Offering terms

Proposed price range
$19.00–$22.00 per share (S-1/A filed 2014-07-18)
Final price
$20.50 per share, within the range (424B1 filed 2014-08-01, an initial public offering)
Shares sold
42,500,000
Gross proceeds
$871,250,000 before underwriting discounts and any over-allotment option
Listing
NYSE under the symbol CTLT
Lead underwriters
Morgan Stanley; J.P. Morgan
Syndicate
BofA Securities; Goldman Sachs; Jefferies; Deutsche Bank; Blackstone Capital Markets; Piper Sandler; Raymond James; Wells Fargo; William Blair; Evercore

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 17

FiledFormWhat it isName as filedEDGAR
2014-01-24S-1S-1 (registration)PTS Holdings Corp.0001193125-14-020114 ↗
2014-02-28S-1/AS-1/A (amendment)Catalent, Inc.0001193125-14-077809 ↗
2014-04-10S-1/AS-1/A (amendment)Catalent, Inc.0001193125-14-137505 ↗
2014-05-05S-1/AS-1/A (amendment)Catalent, Inc.0001193125-14-180811 ↗
2014-05-30S-1/AS-1/A (amendment)Catalent, Inc.0001193125-14-219678 ↗
2014-07-18S-1/AS-1/A (amendment)Catalent, Inc.0001193125-14-272217 ↗
2014-07-30EFFECTEFFECT (declared effective)Catalent, Inc.9999999995-14-002299 ↗
2014-08-01424B1424B1 (final prospectus)Catalent, Inc.0001193125-14-291034 ↗
2015-02-20S-1S-1 (registration)Catalent, Inc.0001193125-15-054962 ↗
2015-03-02S-1/AS-1/A (amendment)Catalent, Inc.0001193125-15-071634 ↗
2015-03-03S-1MEFS-1MEF (added securities)Catalent, Inc.0001193125-15-075556 ↗
2015-03-03EFFECTEFFECT (declared effective)Catalent, Inc.9999999995-15-000527 ↗
2015-03-04424B4424B4 (final prospectus)Catalent, Inc.0001193125-15-076969 ↗
2015-05-22S-1S-1 (registration)Catalent, Inc.0001193125-15-198813 ↗
2015-06-01S-1/AS-1/A (amendment)Catalent, Inc.0001193125-15-207648 ↗
2015-06-02EFFECTEFFECT (declared effective)Catalent, Inc.9999999995-15-001507 ↗
2015-06-03424B1424B1 (final prospectus)Catalent, Inc.0001193125-15-212136 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2014-07-18S-1/Aregistration statement$19.00–$22.0042,500,000-NYSE CTLT12primary document; range, shares headline, cover names 12document ↗
2014-08-01424B1final prospectus$20.5042,500,000$871,250,000NYSE CTLT12primary document; price sentence, shares headline, proceeds table, cover names 12document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BLACKSTONE CAPITAL PARTNERS V L PTenPercentOwner62014–2016
Blackstone Group L.P.TenPercentOwner62014–2016
Blackstone Group Management L.L.C.TenPercentOwner62014–2016
Blackstone Healthcare Partners L.L.C.TenPercentOwner72014–2016
Blackstone Holdings III GP L.P.TenPercentOwner62014–2016
Blackstone Holdings III GP Management L.L.C.TenPercentOwner62014–2016
Blackstone Holdings III L.P.TenPercentOwner62014–2016
Blackstone Management Associates V L.L.C.TenPercentOwner62014–2016
BMA V L.L.C.TenPercentOwner62014–2016
BOOTH MELVIN DDirector32014–2016
Chiminski John RDirector,OfficerChair & CEO; Chair, President & CEO; Executive Chair; President & CEO; See Remarks432014–2022
Chu ChinhDirector12014
CLASSON ROLF ADirector132014–2024
Downie WilliamOfficerSee Remarks; SVP, Global Sales & Marketing172014–2019
Gennadios AristipposOfficerGroup Pres. Pharma & Consumer; President Softgel & Oral Tech; President, Softgel Tech.; See Remarks392014–2024
Houlton ScottOfficerSee Remarks52014–2015
Johnson SharonOfficerSee Remarks72014–2017
Kurt NielsenOfficerSee Remarks32014–2015
Leonard StephenOfficerSee Remarks62014–2016
Littlejohns BarryOfficerPresident, Biologics & SDD; President - DDS; See Remarks192014–2019
McEvoy BruceDirector12014
Miyamoto LanceOfficerSee Remarks; SVP - Human Resources; SVP, Human Resources162014–2019
QUELLA JAMESDirector52014–2017
SCHWARZMAN STEPHEN ATenPercentOwner62014–2016
STAHL JACK LDirector132014–2024
WALSH MATTHEW MOfficerEVP & Chief Financial Officer; See Remarks142014–2017
Fasman Steven LOfficerEVP & Chief Admin Officer; See Remarks; SVP & General Counsel382014–2023
LUCIER GREGORY TDirector192015–2024
CARROLL J MARTINDirector172015–2024
Joseph WettenyOfficerPresident - CSS; See Remarks; SVP & Chief Financial Officer242015–2021
MOREL DONALD E JRDirector152015–2024
Dolan ChristineOfficerSee Remarks; SVP - Product Development92016–2017
Maselli AlessandroDirector,Officer; OfficerPresident & CEO; President & COO; See remarks; SVP - Global Operations; SVP, Global Operations302016–2024
Roehrhoff UweDirector42016–2017
Balachandran MadhavanDirector92017–2023
Gunther ScottOfficerSee Remarks; SVP, Quality & Reg. Affairs332017–2024
Arnold JonathanOfficerPresident, Oral Drug Delivery; Pres. Oral & Specialty Deliv.; SVP, CCO & Div. Head BioP Del.; SVP & Chief Commercial Ofcr272017–2023
Crane Rosemary ADirector82018–2023person page Fuzzy
GREISCH JOHN JDirector; Director,OfficerExecutive Chair112018–2024person page Fuzzy
Kreuzburg ChristaDirector122018–2024
HEGWOOD PAUL W JROfficerPresident, CSS72018–2019
Schmidt Kay AOfficerSVP, Enterprise Functions; SVP, Technical Operations192019–2022
BUZY PETER LOfficerPresident, Gene Therapy62019–2020
Zippelius PeterDirector92019–2022
Pravda RicardoOfficerChief Transformation Officer; SVP & Chief HR Officer; SVP, Human Resources212019–2023
Grippo Michael JOfficerSVP, Strategy & Corp. Dev.232019–2023person page Fuzzy
Flynn KarenDirector; OfficerChief Commercial Officer; Pres. Biologics & CCO122020–2023
Whitlow Ricci SOfficerPresident, CSS82020–2022
Barber Michael JDirector72021–2024
Castellano Thomas POfficerSVP, Chief Financial Officer72021–2022
Hopson RickyOfficerPres. BioProduct Delivery, CoS; Pres, Clinical Dev & Supply; Pres. Clinical Dev Supply Div; VP, Chief Accounting Officer172021–2024
Carletti LorenzoOfficerSVP Global Ops Ph & Cons Hlth; SVP Global Ops Small Molecule62021–2023
Gargiulo MarioOfficerSVP Global Ops Biologics; SVP Global Ops Large Molecule; SVP, Ops, Biologics Europe52021–2023
NoneDirector12021
Boerman ManjaOfficerPres. BioModalities Division42022–2023
Hawkeswood Thomas WOfficerPres. Pharma Prod Delivery Div62022–2023
Hunt PatriciaOfficerPres. Consumer Health Div62022–2023
Lickfold CharlesOfficerSVP, CIO42022–2023
Riley Michael A.OfficerPres. Bio Product Delivery Div32022
Santiago Karen MurphyOfficerVP & Chief Accounting Officer32022–2023
Zayas RicardoOfficerSVP, Operations, Biologics NA22023
Ferraro Joseph AnthonyOfficerSVP, General Counsel, CCO72023–2024
Masanovich MattiOfficerSVP, Chief Financial Officer52023–2024
DAMELIO FRANK ADirector52023–2024person page Fuzzy
Evoli LisaOfficerSVP, Chief HR Officer42023–2024
Okey StephanieDirector52023–2024
Ryan Michelle RDirector72023–2024
Barg StevenDirector52023–2024
McErlane DavidOfficerGroup President, Biologics42023–2024
Hatzfeld MichaelOfficerChief Accounting Officer42024

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2019-05-31Catalent, Inc.Pharmaceuticals$650,000,000$650,000,00041

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationCATALENT, INCNJState business registriesname and state
Political committeeCATALENT, INC. PAC (connected to CATALENT, INC.)NJCampaign finance (FEC)name and state
Form D issuerCatalent, Inc.NJForm D private offeringsCIK (EXACT)
Lobbying clientCATALENT, INC.NJFederal lobbying (LDA)name and state
SEC filerCatalent, Inc.SEC filers (EDGAR)CIK (EXACT)
Person pageFrank A D'AmelioPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
Person pageJohn J GreischPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer)
Person pageMichael J GrippoPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)
Person pageRosemary A CranePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, NJ first:

More with this interest.

In other datasets, the same topic (Health) in NJ:

Interests: Pharmaceutical Preparations · Health